Merus NV at Jefferies Healthcare Conference Transcript
Hi, everyone. Thanks for joining us. My name is Maury Raycroft. And I'm one of the biotech analysts at Jefferies. I'd like to welcome Bill Lundberg, the CEO of Merus. And we're going to do a fireside chat discussion. So maybe to start off, Bill, if you want to give a brief intro to Merus.
Merus is an oncology-focused bispecific and multi-specific antibody company based on foundational technology that allows us to look through hundreds of thousands of potential candidate molecules to find the best ones to bring in the clinic. And while we don't necessarily think that guarantees success in the clinic based on the recent clinical data, we've been able to show across our portfolio. We're really encouraged that it may give us an advantage as we bring clinical candidates forward.
We have four clinical-stage candidates, I'm sure we'll discuss today. Three of which are really showing legs. So we're really quite encouraged
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |